Search results

You're right. I don't see any direct mentions of any specific criteria, except listed at the bottom as references. Maybe it'd be good to include something about specific existing criteria. It might be helpful for people who are curious if their symptoms align with a more "official" source.

There are several criteria currently in use. I'm not totally sure what "consensus" criteria specifically means. Fukuda (CDC 1994) Canadian Consensus Criteria (CCC 2003) International Consensus Criteria (ICC 2011) Institute of Medicine (IOM 2015) National Institute for Health and Care Excellence...

I think they named the wrong gene. OLFM4 isn't one of the 259 core genes in this paper's Extended Table 3, as far as I can tell. On the other hand, CSE1L is a DecodeME tier 1 gene that is one of this study's core genes. And while DCC is one of the PrecisionLife core genes, it wasn't a tier 1 or...

I thought more about it, and came to the conclusion that this might be an inaccurate interpretation. Maybe it does add some confidence about the loci - seeing them come up again with a totally different method.

Basically, the point of the above paper is, a change in one group being significant while a change in another is not does not mean that the difference between the groups is statistically significant. As an extreme example to illustrate the point, one can imagine a group of 500 people receiving...

The Difference Between “Significant” and “Not Significant” is not Itself Statistically Significant Gelman, Andrew; Stern, Hal Web | DOI | PDF | The American Statistician --- Edit: I found another good article on this topic: Erroneous analyses of interactions in neuroscience: a problem of...

I read further and they literally say the same thing, except in explaining why the placebo group didn't improve when they were crossed over to get the intervention: So the active group significantly improved but the placebo group didn't in the first part - apparently evidence the intervention...

In the sense that they found significant SNPs in the same 8 areas, sure. But since it's not really new data, I'd say that the replication mainly adds confidence about their method being reliable (and thus potentially having more confidence in the other findings), rather than adding much...

I think they also relied on the UK BioBank, but it was mainly based on DecodeME, so I wouldn't call it replicating in independent datasets. Here's the bit about overlap with the 8 original DecodeME loci, which is based on SNPs in double refined signatures, which were created based on DecodeME.

It seems like the main result is based on testing significance within each group separately and comparing p-values. This isn't how you demonstrate that one group differs significantly from another group. Also, there are different numbers of people in each group: If we assume each group might...

Many of the same authors as the recent preprint: Evidence of Accumulating Neurophysiologic Dysfunction in Persistent Post-COVID Fatigue, 2025, Germann et al

Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue (PAuSing-pCF) [Line breaks added] Abstract Even mild SARS-CoV-2 infection can lead to post-COVID syndrome, 70% of such patients have post-COVID fatigue (pCF). Many physiological abnormalities observed in pCF could be...

The results section says: But the discussion gives a different hazard ratio for 3 to 6 months. I'm not sure if this is referring to something else. And the discussion talks about a figure for mortality that I can't find in the results or supplementary file, and I don't see anything about...

“We need to be believed": A qualitative interview study on the Hertfordshire (UK) Long Covid and Physical Activity Study [Line breaks added] Background The Covid-19 pandemic has led to the emergence of Long Covid, a complex multisystem condition characterised by persistent symptoms lasting...

Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 [Line breaks added] Abstract The guidelines presented herewith are based on the “Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 (PASC)” published in Infection & Chemotherapy in...

SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients Background Long COVID presents significant health challenges, especially for patients with type 2 diabetes. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors...

I'm becoming more hopeful that this could be useful as I add more findings from different studies. I've saved 43 studies so far. I just added the 19 genes highlighted in the text of a 2016 GWAS (Schlauch et al), then did a search to see if any of those genes had been saved for any other studies...

Long-Term Health Effects of COVID-19 in Tunisia, 2020–2021 Background Some patients suffer from persistent symptoms following a COVID-19 infection, referred to as long COVID. The aims of the study were to estimate the prevalence of long COVID and study its determinants in Tunisia. Methods...

Russian journal. One author. There's no registration on ClinicalTrials.gov with that number. It refers to a figure 1, but I don't see any figures. That seems like a very significant result [Edit: I just mean low p-value], assuming there was good blinding. Is it because so many of them are...

Impact of Micronutrients on Recovery and Rehabilitation Strategies in Long COVID Saidov F.A. Abstract Long COVID, or post-acute COVID-19 syndrome, is characterized by persistent symptoms and functional impairment following acute SARS-CoV-2 infection. Micronutrients such as vitamins and trace...